Parima Hirunwiwatkul

Parima Hirunwiwatkul

Auto-generated profile, based on publicly available information

Parima Hirunwiwatkul

Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2018 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
CTChernkwan Titirungruang
Chernkwan Titirungruang
KSKachorn Seresirikachorn
Kachorn Seresirikachorn
PKP. Kasemsuwan
P. Kasemsuwan
PHP. Hirunwiwatkul
P. Hirunwiwatkul

15 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PHParima Hirunwiwatkul
Parima Hirunwiwatkul
WSWajamon Supawatjariyakul
Wajamon Supawatjariyakul
SJSupharat Jariyakosol
Supharat Jariyakosol
SASupanut Apinyawasisuk
Supanut Apinyawasisuk
JSJiruth Sriratanaban
Jiruth Sriratanaban
PCPareena Chaitanuwong
Pareena Chaitanuwong
Purpose: To compare Thais’ health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design: Prospective-observational study. Participants: BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods: Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results: 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion: Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.

12 December 2023 in International Journal of Telerehabilitation
Verified
Journal Article
Open access
PDF file
PHParima Hirunwiwatkul
Parima Hirunwiwatkul
PPPunnaka Pongpanich
Punnaka Pongpanich
WTWasee Tulvatana
Wasee Tulvatana
SJSupharat Jariyakosol
Supharat Jariyakosol
WPWarongporn Phuenpathom
Warongporn Phuenpathom
CNChaichana Nimnuan
Chaichana Nimnuan
This cross-sectional validation study aimed to translate, cross-culturally adapt, and investigate the psychometric properties of a Thai version of the Telehealth Usability Questionnaire (T-TUQ). Two hundred and ten Thai participants, mean age of 61.2±15.2 years, were recruited from three specialty clinics: 50 (23.8%) hematology, 70 (33.3%) movement disorders, and 90 (42.9%) general neurology. The T-TUQ was translated from the original English version to produce a Thai language version. Back translation and pilot cognitive interviews were completed. All five subscales (usefulness, ease of use, effectiveness, reliability, and satisfaction) showed excellent internal consistency (alpha >0.80), displayed by Cronbach's alpha coefficient of 0.83, 0.94, 0.86, 0.83, and 0.92, respectively. For construct validity, exploratory factor analysis revealed two dimensions from eigenvalues and scree plot, defined as utility and accessibility subscales. In conclusion, the T-TUQ could be a reliable and valid instrument to evaluate the usability of telehealth with a Thai population.

22 October 2021 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
TJThanchat Jienmaneechotchai
Thanchat Jienmaneechotchai
SASupanut Apinyawasisuk
Supanut Apinyawasisuk
SJSupharat Jariyakosol
Supharat Jariyakosol
PHParima Hirunwiwatkul
Parima Hirunwiwatkul
Background: Lid fatigability test (LFT), Cogan lid twitch (CLT), and forced eyelids closure test (FECT) are simple clinical screening tests for ocular myasthenia gravis (OMG). However, these tests are subjectively interpreted. We thus evaluated the interobserver and intra-observer reliability of each test. Methods: The 3 eyelid tests were performed in ptotic patients associated with various conditions, including OMG and others. Video clips of all tests were recorded using smartphone with built-in camera in the following order; LFT, CLT, and FECT. All video clips were distributed to 3 neuro-ophthalmologists and 3 general ophthalmologists, who were trained to evaluate the tests using a single standard instruction. After 3 months, all video clips were re-organized for the second evaluation. Interobserver and intra-observer reliability were calculated using Cohens' Kappa coefficient and Fleiss Kappa statistic. Results: The 3 eyelid tests were performed and recorded in 35 patients, which included the diagnosis of OMG, levator muscle dehiscence, partial oculomotor nerve palsy, and Horner syndrome. CLT received moderate-to-substantial interobserver reliability in neuro-ophthalmologist group (Fleiss Kappa 0.77 [95% CI 0.60–0.94] and 0.66 [95% CI 0.46–0.85] in first and second evaluation respectively), but the results varied in general ophthalmologist group (Fleiss Kappa 0.58 [95% CI 0.37–0.79] and 0.54 [95% CI 0.33–0.76] in first and second evaluation respectively). FECT and LFT received lower interobserver reliability in both groups. CLT also received moderate-to-almost perfect intra-observer reliability in neuro-ophthalmologist group (Cohen Kappa 0.55, 0.58, and 0.92), whereas FECT and LFT received lower intra-observer reliability. The intra-observer reliability varied among general ophthalmologists for all 3 eyelid tests. Conclusions: CLT is the most reliable test among the 3 eyelid tests. However, all tests should be interpreted with caution by general ophthalmologists.

1 October 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
PHParima Hirunwiwatkul
Parima Hirunwiwatkul
UPUnchalee Permsuwan
Unchalee Permsuwan
SNSureerat Ngamkiatphaisan
Sureerat Ngamkiatphaisan
NCNiphon Chirapapaisan
Niphon Chirapapaisan
JSJiruth Sriratanaban
Jiruth Sriratanaban
Objective: Severe blepharospasm is a disabling neurological condition that significantly affects patients’ quality of life. Botulinum toxin type A (BoNT-A) is considered the standard treatment due to its targeted therapeutic effect and fewer systemic side effects compared to oral medications. However, its high cost poses a barrier to access within Thailand’s healthcare system. This study aimed to assess the budget impact of introducing BoNT-A treatment (Onabotulinumtoxin A and Abobotulinumtoxin A) compared with current oral medications for severe blepharospasm in Thailand. Methods: A budget impact model was developed from the perspective of Thailand’s healthcare system over a 5-year time horizon. The current scenario (oral medications use) was compared with a new scenario involving BoNT-A treatment. The costs considered included drug acquisition, outpatient visits, and accident-related injuries. The base-case assumed gradual uptake of BoNT-A (30% in year 1, 50% in year 2, and 100% from year 3). Sensitivity analyses explored full uptake from year 1, no dose sharing, and inclusion of injury-related costs. Results: Excluding injury-related costs, the 5-year net budget impact (NBI) was 7.91 million THB (223,040 USD) for onabotulinumtoxin A and 7.27 million THB (205,064 USD) for abobotulinumtoxin A. Including injury-related costs reduced the NBI to 4.20 million THB (118,564 USD) and 3.57 million THB (100,588 USD), respectively. Without dose sharing, the NBI rose significantly, reaching 40.5 million THB (1.14 million USD) for abobotulinumtoxin A. Conclusion: BoNT-A treatment increases healthcare costs, primarily due to drug costs. However, reduced injury costs and dose-sharing strategies may enhance affordability and support BoNT-A’s inclusion in Thailand’s National List of Essential Medicine.

21 April 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PHParima Hirunwiwatkul
Parima Hirunwiwatkul
UPUnchalee Permsuwan
Unchalee Permsuwan
SNSureerat Ngamkiatphaisan
Sureerat Ngamkiatphaisan
NCNiphon Chirapapaisan
Niphon Chirapapaisan
JSJiruth Sriratanaban
Jiruth Sriratanaban
Background: Blepharospasm is a chronic facial movement disorder affecting a person’s ability to work, causing depression, pain, and a reduced quality of life (QoL). Botulinum toxin type A (BoNT-A) treatment can improve these conditions; however, its cost remains a significant barrier for inclusion of this indication into the Thai National List of Essential Medicine. Objectives: This study aimed to assess the cost-effectiveness of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A) treatment compared to oral medication treatment in patients with severe blepharospasm from a societal perspective. Methods: A cost-utility analysis using a two-part model was conducted to analyze lifetime costs and quality-adjusted life-years (QALYs). Inputs were mainly obtained from real-world evidence of 159 Thai patients with blepharospasm. Costs and outcomes were discounted at 3% annually and presented as 2023 value. Incremental cost-effectiveness ratios (ICERs) were estimated. Deterministic and probabilistic sensitivity analyses were also conducted. Results: In comparison to standard oral medication, both onaBoNT-A and aboBoNT-A incurred greater lifetime cost (3,055 USD, 2,889 USD vs 1,926 USD) while gaining additional QALYs (6.94 years, 6.94 years vs 6.53 years). The estimated ICERs were 2,722 USD/QALY for onaBoNT-A and 2,323 USD/QALY for aboBoNT-A. Utility and cost of BoNT-A were important determinants in the sensitivity analysis. Conclusion: Among patients with severe blepharospasm, both onaBoNT-A and aboBoNT-A were considered a cost-effective strategy under the Thai willingness to pay threshold of 4,613 USD/QALY. Having aboBoNT-A was slightly more favorable due to lower cost, using a conversion ratio of 1U of onaBoNT-A: 3U of aboBoNT-A.